SVB Leerink Reiterates Outperform on Deciphera Pharmaceuticals, Maintains $30 Price Target
SVB Leerink analyst Andrew Berens reiterates Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Outperform and maintains $30 price target.
SVB Leerink Maintains Outperform on Deciphera Pharmaceuticals, Raises Price Target to $30
SVB Leerink analyst Andrew Berens maintains Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Outperform and raises the price target from $28 to $30.
Earnings Scheduled For February 7, 2023
Companies Reporting Before The Bell
• BP (NYSE:BP) is likely to report quarterly earnings at $1.67 per share on revenue of $53.79 billion.
$30M Bet On Deciphera Pharmaceuticals? Check Out These 4 Stocks Insiders Are Buying
Although US stocks closed mixed on Tuesday, there were a few notable insider trades.
Deciphera Pharmaceuticals Announces Pricing Of $125M Public Offering Of 6,944,445 Shares Of Common Stock At A Price Of $18/Share
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced the
Why Jupiter Wellness Shares Are Trading Lower By Around 40%? Here Are Other Stocks Moving In Thursday’s Mid-Day Session
Gainers
Genius Group Limited (NYSE: GNS) jumped 87% to $1.00. Genius Group authorized issue of special dividend and appointed Timothy Murphy to lead Illegal Trading Task Force.
Dow Falls 200 Points; Jobless Claims Drop To 4-Month Low
U.S. stocks traded lower this morning, with the Dow Jones dropping around 200 points on Thursday.
Benzinga’s Top Ratings Upgrades, Downgrades For January 6, 2023
Upgrades Piper Sandler upgraded the previous rating for Aligos Therapeutics Inc (NASDAQ:ALGS) from Neutral to Overweight. Aligos Therapeutics…
JonesTrading Upgrades Deciphera Pharmaceuticals to Hold
JonesTrading analyst Soumit Roy upgrades Deciphera Pharmaceuticals (NASDAQ:DCPH) from Sell to Hold.
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea.